Business & regional news

Harmony™ Transcatheter Pulmonary Valve system approval expands minimally invasive treatment options for patients with congenital heart disease across European Union

Two data releases at London Valves 2024 build on Evolut’s legacy of valve design and performance: Optimize PRO study demonstrates improved procedure efficiencies and valve performance Pooled...

Collaboration with health technology company Tempus seeks to identify causes for undertreatment of minority patients with heart valve disease who may benefit from minimally invasive therapies

Newest-generation Evolut TAVI system builds on its market leading valve performance and durability with enhanced coronary access

New York Valves 2024: Late-breaking data included a SMART Trial secondary analysis showing significantly less bioprosthetic valve dysfunction with Evolut TAV across the entire range of small annulus areas when compared with the Edwards Sapien 3™ TAV platform, and CoreValve-Evolut pooled analysis demonstrating valve performance and durability benefits versus surgery.